Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)

A Ph.2, single-arm, monocentric, trial of neo-adjiuvant chemo-immunotherapy for stage III, PD-L1 positive, NSCLC. Adults and smokers (past or current) diagnosed with stage III NSCLC without driver molecular alterations (EGFR, ALK, ROS1, RET).

Trial Details

NCT ID
NCT07264647
Phase
PHASE2
Sponsor
Fondazione Ricerca Traslazionale
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Tislelizumab
  • surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
  • Chemoradiotherapy
Locations (sample)
  • Rome, Roma (RM), Italy|41.89193,12.51133

Key Eligibility Criteria

  • Histologically confirmed stage III disease.
  • PD-L1 TPS ≥ 1% according to local testing.
  • No evidence of EGFR mutations or ALK or ROS1 or RET rearrangements by local testing.
  • Mandatory baseline multidisciplinary assessment to confirm suitability of patient to local treatment with curative intent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →